Background: Given that diabetes-associated complications are closely associated with neuroinflammation, it is imperative to study potential changes in neuroinflammatory modulators in the central nervous system of diabetic primates. Methods: The mRNA levels of pro-and anti-inflammatory cytokines, tolllike receptors (TLRs), growth factors, and cannabinoid receptors were compared in the spinal dorsal horn (SDH) and thalamus of naturally occurring type 2 diabetic monkeys and an age-matched control group using reverse transcription and quantitative real-time polymerase chain reaction. Results: In the SDH of diabetic monkeys, mRNA levels of proinflammatory cytokines (i.e. interleukin [IL]-1β and tumor necrosis factor [TNF] α), TLR1, and TLR2 were increased, whereas mRNA levels of IL-10, an antiinflammatory cytokine, were decreased. No changes were observed in the mRNA levels of growth factors and cannabinoid receptors. In line with the mRNA data, TNFα immunoreactivity was significantly increased in diabetic monkeys. Moreover, mRNA expression levels of IL-1β, TNFα, TLR1, and TLR2 in the SDH were positively correlated with plasma glucose concentrations in all monkeys. Conclusions: Several ligands and receptors involved in neuroinflammation are simultaneously dysregulated in the spinal cord of diabetic monkeys. This primate disease model will facilitate the design of novel treatment approaches to ameliorate neuroinflammation-driven adverse effects in diabetic patients.
Introduction
Type 2 diabetes mellitus (T2DM), a long-term metabolic disorder, severely affects the eyes, kidneys, and peripheral and autonomic nervous systems, accounting for vision loss, end-stage kidney disease, amputations, and an increased risk of cardiovascular disease. 1, 2 Neuropathy is one of the intractable symptoms of T2DM, and more than 50% of T2DM patients experience sensory dysfunction. [3] [4] [5] Given that T2DM-associated complications are closely associated with neuroinflammation, [6] [7] [8] [9] [10] characterization of neuroinflammatory events (e.g. altered expression of inflammatory ligands and receptors for sensory processing in the central nervous system [CNS] ) in diabetic primates could substantially facilitate the development of novel treatment options. Glial activation and upregulation of inflammatory mediators such as chemokines CC-chemokine ligand 2 (CCL2) and CXC-chemokine ligand 10 (CXCL10) have been reported in rodents with T2DM. 11, 12 Compared with rodent models, there are numerous changes in the spinal dorsal horn (SDH) of monkeys with T2DM. In addition to activated microglia and astrocytes, three chemokine ligand-receptor systems, namely CCL2-CCR2, CCL3-CCR1/5, and CCL4-CCR5, and multiple chemokine receptors (i.e. CCR4, CCR6, CCR8, CCR10, CXCR3, CXCR5, and CXCR6) are simultaneously upregulated. 13 In addition, mRNA expression levels of classical opioid receptor subtypes μ, κ, and δ are downregulated. 13 These findings demonstrate that there is potential cross-talk between chemokines and opioids in the spinal cord of diabetic monkeys. 13 However, potential changes in other ligand-receptor systems associated with neuroinflammation in primates with T2DM are virtually unknown.
Neuroinflammatory processes are classified as either pro-or anti-inflammatory events, and are dynamically regulated by several mediators. [14] [15] [16] Maintaining a steady balance between pro-and anti-inflammatory mediators is required for homeostasis in the CNS. 17, 18 Among these modulators, cytokines, toll-like receptors (TLRs), growth factors, and cannabinoid receptors differentially affect inflammatory processes in rodents. 15, [19] [20] [21] [22] [23] [24] [25] Proinflammatory cytokines, such as interleukin (IL)-1β and tumor necrosis factor (TNF)-α, are well characterized in the spinal dorsal horn (SDH). Pharmacological and genetic manipulations of these mediators in rodents relieve or modulate intractable inflammatory diseases. [26] [27] [28] Although rodent studies have documented the functional significance of these neuroinflammatory modulators, the translatability of their functional changes from rodents to primates with chronic diseases remains unclear.
In monkeys with T2DM, considerable changes in cutaneous innervation were shown to be consistent with sensory deficits experienced by patients with diabetic neuropathy. 29, 30 Thus, diabetic monkeys can be a valuable model for studying T2DM pathophysiology. 31, 32 In the present study, we examined potential changes in neuroinflammatory modulators in the CNS of diabetic monkeys. Because the SDH and thalamus play a fundamental role in sensory processing, 33, 34 we specifically analyzed pro-and anti-inflammatory cytokines, TLRs, growth factors, and cannabinoid receptors in the SDH and thalamus of monkeys with T2DM. These findings will facilitate the design of novel treatments that may ameliorate the adverse events associated with T2DM.
Methods

Animals
All experimental procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the US National Institutes of Health (Bethesda, MD, USA; see https:// grants.nih.gov/grants/olaw/Guide-for-the-care-and-use-oflaboratory-animals.pdf, accessed 2 March 2015) and approved by the Institutional Animal Care and Use Committee of Wake Forest University School of Medicine (Winston-Salem, NC, USA). Seven (one male, six female) cynomolgus macaques (Macaca fascicularis) diagnosed with 3-6 years of spontaneously occurring type 2 diabetes and six (one male, five female) non-diabetic (control) cynomolgus macaques were used. Animals were housed individually in a room with a temperature of [21] [22] [23] [24] [25] C, 40%-60% relative humidity, and a 12-h light-dark cycle at Wake Forest University Primate Center. Animals were fed with regular chow (5038; LabDiet, St Louis, MO, USA), fresh fruits, and water ad libitum. The general characteristics of all animals are given in Table S1 , available as Supplementary Material to this paper. Animals were diagnosed with diabetes by veterinarians. These animals showed increased glucose, cholesterol, triglycerides, and HbA1C levels, which are similar to those of other diabetic monkeys. 32, 35, 36 Reverse transcription and quantitative real-time polymerase chain reaction Detailed procedures for tissue collection and reverse transcription and quantitative real-time polymerase chain reaction (RT-qPCR) have been described elsewhere. 13 Briefly, the skull and spinal column were cut open to expose the brain and spinal cord. The ventral posterior thalamus and L4 spinal dorsal horn tissues were dissected according to the histology atlas of the Rhesus monkey brain. 37 The TRIzol Plus RNA Purification Kit (Thermo Fisher Scientific, Waltham, MA, USA) was used to isolate total RNA from tissues. One microgram purified total RNA was converted to cDNA by reverse transcription using random primers (Promega, Madison, WI, USA), dNTP mix (Thermo Fisher Scientific), and M-MLV reverse transcriptase (Promega). Quantitative PCR was performed using the synthesized cDNA, gene-specific primers (Table 1 ; Sigma-Aldrich, St Louis, MO, USA), and iTaq Universal SYBR Green Supermix with iCycler and iQ Real-Time PCR systems (Bio-Rad, Hercules, CA, USA). Reactions were performed under the following conditions: 10 min at 95 C, followed by 50 cycles of two steps (i.e. 20 s at 95 C and 40 s at 60 or 62 C, depending on the melting temperature of the primers). According to the previously characterized comparative threshold cycle (C T ) method, 38 the C T value was defined as the PCR cycle at which the relative fluorescent unit (RFU) crossed a threshold line (100 RFU). The mRNA expression level of each gene was quantified based on the average C T value from three replicates and was normalized against that of β-actin (ACTB) using the following formula:
All data from individual monkeys are presented as the mean AE SEM. Data were analyzed using unpaired t-tests. Correlation analysis was performed using Pearson's correlation coefficient. The criterion for significance was set at P < 0.05.
Immunohistochemistry
Spinal cord tissues were fixed in 4% paraformaldehyde and cryoprotected in phosphate-buffered saline (PBS) containing 30% sucrose. Tissues were subsequently embedded in OCT compound (Sakura Finetek, Torrance, CA, USA) and stored at −80 C until use. Frozen tissues were cut at a thickness of 30 μm using a cryostat (Leica CM3050S; Leica Biosystems, Wetzlar, Germany). Tissue sections were treated with 0.3% H 2 O 2 for 15 min, washed with PBS, and blocked with PBS containing 0.3% Triton X-100 and 3% normal donkey Transforming growth factor-β1
Cannabinoid receptor 2 TCCACTGATTCCCAACGACT TGATGGGCTTTCCAGAGAAC serum at room temperature for 30 min. The sections were then incubated with a primary antibody against TNFα (rabbit polyclonal, 1:500 dilution; ab6671, Abcam, Cambridge, MA, USA) at 4 C overnight. The next day, sections were rinsed in PBS containing 0.1% Triton X-100 (PBST) and incubated with biotinylated secondary antibody (1:400 dilution; Jackson ImmunoResearch Laboratories, West Grove, PA, USA) at room temperature for 1 h. All antibodies were diluted in PBST containing 1% normal donkey serum. After the incubation, sections were rinsed in PBST and incubated with Vectastain ABC kit (PK-6100; Vector Laboratories, Burlingame, CA) for 30 min at room temperature. After rinsing in PBST, sections were stained using a 3,3 0 -diaminobenzidine (DAB) substrate kit (SK-4100; Vector Laboratories), mounted on glass slides to air dry, dehydrated through a graded series of ethanol and xylene, and cover-slipped with DPX mounting medium (Sigma-Aldrich).
Image analysis
Images of spinal cord sections were acquired at a magnification of ×10 using a Nikon Eclipse Ni fluorescent and brightfield microscope (Nikon, Tokyo, Japan). ImageJ software (National Institutes of Health, Bethesda, MD, USA) was used to quantify TNFα immunostaining in the superficial laminae (I-II) of four randomly selected lumbar spinal cord sections from each animal. Data are presented as the fractional area, which reflects the percentage of the sampled area that fell within a defined density threshold. The individual who analyzed the images was blinded to the experimental conditions.
Results
Upregulation of proinflammatory cytokines in the SDH of diabetic monkeys
Expression of IL-1β, IL-6, IL-18, TNFα, and interferon-γ (IFNγ) mRNA was evaluated using RT-qPCR in order to determine whether these pro-inflammatory cytokines were altered in the SDH and thalamus of diabetic monkeys. In the SDH of non-diabetic monkeys, basal expression of IL-18 mRNA was the highest, followed by IL-1β and TNFα (Fig. 1a) . In the SDH of diabetic monkeys, compared with non-diabetic monkeys, upregulated expression of IL-1β (1.3-fold increase; 95% confidence interval [CI] -0.563, 0.057; t = 1.80, d.f. = 11, r 2 = 0.23, P = 0.049) and TNFα (1.3-fold increase; 95% CI -0.691, 0.039; t = 1.97, d.f. = 11, r 2 = 0.26, P = 0.038) mRNA was noted (Fig. 1b) . In the thalamus of non-diabetic monkeys, basal mRNA expression patterns of these cytokines were similar to those of cytokines in the SDH (Fig. 1c) . However, there were no significant changes in the mRNA expression of any of these cytokine genes between the diabetic and non-diabetic monkeys (Fig. 1d) . Interestingly, expression of IL-1β and TNFα mRNA in the SDH was positively correlated with plasma glucose levels of all monkeys (Fig. S1 ). To examine whether there was a change in protein levels in the SDH of diabetic monkeys, immunohistochemistry for TNFα was performed and analyzed. In line with qPCR data, TNFα immunoreactivity was significantly increased in diabetic compared with nondiabetic monkeys (1.8-fold increase; 95% CI -2.074, 33.99; t = 1.95, d.f. = 11, r 2 = 0.26, P = 0.039; Fig. 2 ).
Changes in anti-inflammatory cytokine expression in the SDH and thalamus of diabetic monkeys
Expression of the IL-1 receptor antagonist (IL-1RN), IL-4, IL-10, IL-13, and IL-18 binding protein (IL-18BP) mRNA was quantified and compared using RT-qPCR to investigate whether there were any changes in these antiinflammatory cytokines in the SDH and thalamus of diabetic monkeys. In the SDH of non-diabetic monkeys, basal mRNA expression of IL-18BP was the highest, followed by IL-1RN and IL-10 (Fig. 3a) . In the SDH of diabetic monkeys, compared with non-diabetic monkeys, IL-18BP expression was upregulated (1.2-fold; 95% CI -0.505, 0.013; t = 2.09, d.f. = 11, r 2 = 0.28, P = 0.030), whereas IL-10 expression was downregulated (0.7-fold; 95% CI -0.039, 0.553; t = 1.91, d.f. = 11, r 2 = 0.25, P = 0.041; Fig. 3b ). In the thalamus of non-diabetic monkeys, basal mRNA expression of IL-18BP was much higher than that of the other four genes (Fig. 3c) . As observed in the SDH, IL-10 expression was also downregulated in the thalamus of diabetic monkeys (0.6-fold; 95% CI -0.019, 0.773; t = 2.10, d.f. = 11, r 2 = 0.29; P = 0.030). However, there was no significant increase in IL-18BP expression in the thalamus of diabetic monkeys (Fig. 3d) . There was no correlation between plasma glucose levels and IL-10 and IL-18BP expression in the SDH or IL-10 expression in the thalamus in any animals ( Figs S2, S3 ).
Upregulation of TLRs in the SDH of diabetic monkeys
To examine whether TLRs were altered in the SDH and thalamus of diabetic monkeys, RT-qPCR was used to determine the mRNA expression of TLR subtypes (i.e. TLR1-TLR10). In the SDH of non-diabetic monkeys, basal TLR4 mRNA expression was the highest, followed by TLR1 and TLR2 (Fig. 4a) . Compared with nondiabetic monkeys, TLR1 (1.2-fold; 95% CI -0.432, 0.008; t = 2.12, d.f. = 11, r 2 = 0.29, P = 0.029) and TLR2 (1.4-fold; 95% CI -0.733 to 0.019; t = 2.09, d.f. = 11, r 2 = 0.28, P = 0.030) mRNA expression was upregulated in the SDH of diabetic monkeys (Fig. 4b) . In the thalamus of non-diabetic monkeys, basal mRNA expression patterns of these 10 TLR subtypes were similar to those in the SDH (Fig. 4c) . Nonetheless, there were no significant changes in the mRNA expression of any of these 10 TLR genes in diabetic compared with non-diabetic monkeys (Fig. 4d) . There was a positive correlation between plasma glucose levels and TLR1 and TLR2 mRNA expression in the SDH in all animals (Fig. S4) .
Expression of growth factors in the SDH and thalamus of diabetic monkeys
Next, we investigated whether the expression of growth factors was altered in the SDH and thalamus of diabetic monkeys by determining the expression of colony-stimulating factor 1 (CSF1), brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), vascular endothelial growth factor (VEGF), glial cell line-derived growth factor (GDNF), and transforming growth factor-β1 (TGFβ1). In the SDH of non-diabetic monkeys, basal expression of CSF1, VEGF, and TGFβ1 mRNA was more abundant than that of other growth factors, such as BDNF (Fig. 5a) . Surprisingly, there were no significant differences in the expression of these genes in the SDH between diabetic and nondiabetic monkeys (Fig. 5b) . In the thalamus of nondiabetic monkeys, basal expression of CSF1, VEGF, and TGFβ1 mRNA was relatively higher than that of GDNF, BDNF, and NGF (Fig. 5c) . However, there were no significant differences in the expression of these genes in the thalamus of diabetic versus nondiabetic monkeys (Fig. 5d) .
Expression of cannabinoid receptors in the SDH and thalamus of diabetic monkeys
Finally, we evaluated the expression of CB1 and CB2 mRNA to determine whether the expression of cannabinoid receptors was altered in the SDH and thalamus of diabetic monkeys. In both the SDH and thalamus of non-diabetic monkeys, basal expression of CB1 mRNA was much higher than that of CB2 mRNA (Fig. 6a,c ). There were no significant changes in either CB1 or CB2 mRNA expression in the SDH and thalamus of diabetic compared with non-diabetic monkeys (Fig. 6b,d ).
Discussion
Herein we report for the first time that IL-1β and TNFα gene expression is upregulated in the spinal cord of diabetic monkeys. Interleukin-1β and TNFα, and their cognate receptors, are located on microglia, astrocytes, and neurons and contribute to neuroinflammation in the CNS. 16, 23, 39, 40 In particular, inhibition of these proinflammatory cytokines using pharmacological or genetic approaches in rodents alleviated the symptoms arising from spinal neuroinflammation. 15, [41] [42] [43] Given that microglia and astrocytes are activated in the SDH of monkeys with T2DM 13 and that neuron-glia interactions are bidirectional, 26, 27 the upregulation of IL-1β and TNFα is closely related to glial activation and spinal neuroinflammation. Future studies are warranted to investigate whether inhibition of both glial activation and proinflammatory cytokines can effectively alleviate neuroinflammation-associated symptoms in patients with T2DM.
Anti-inflammatory cytokines play a critical role in the suppression and resolution of inflammation, 44, 45 which is a key component in the homeostatic control of neuroinflammation. In the present study, IL-10 expression was downregulated in the SDH and thalamus of diabetic monkeys. According to previous findings, IL-10 expression in the SDH controls neuroinflammation in different rodent models. 46, 47 Intrathecal delivery of IL-10 prevented the expression of pro-inflammatory cytokines, such as IL-1β and TNFα, and relieved symptoms due to spinal neuroinflammation. [48] [49] [50] Conversely, the functional role of IL-10 in the thalamus has not been characterized in animals. To our knowledge, the present study is the first to report a correlation between central IL-10 expression and T2DM in primates. In future studies, it would be interesting to investigate the function of IL-10 in modulating spinal neuroinflammation in diabetic monkeys. Unlike IL-10 expression, in the present study IL-18BP expression was upregulated in the SDH of diabetic monkeys. Given that IL-18BP counteracts the function of IL-18, which involves glial activation and neuroinflammation, 51 upregulation of IL-18BP in the SDH of diabetic monkeys may be one of the homeostatic mechanisms for suppressing the function of IL-18. 52 Overall, the balance between pro-and anti-inflammatory cytokines is critical for modulating neuroinflammation in the CNS of diabetic monkeys. Of all the TLR subtypes examined herein, mRNA expression of TLR1 and TLR2 was upregulated in the SDH of diabetic monkeys. Growing evidence demonstrates that TLR2 is upregulated in the SDH and participates in glial activation and cytokine expression in rodents with nerve injury. 53, 54 Importantly, TLR2 and TLR4 were upregulated and accounted for spinal neuroinflammation in patients with amyotrophic lateral sclerosis. 55 Toll-like receptor 2 forms heterodimers with TLR1, and the TLR1-TLR2 heterodimer is involved in glial activation and upregulation of inflammatory mediators that contribute to pathological conditions. 56, 57 Further investigations into the functional roles of TLR1 and TLR2 in the SDH of diabetic monkeys is necessary. As a well-characterized neuroinflammatory mediator, 19, 39, 40, 54 it was surprising to find that, although TLR4 was upregulated in the SDH of diabetic mice, 12 there was no change in TLR4 expression in the SDH and thalamus of diabetic monkeys in the present study.
Although some growth factors are known as inflammatory modulators, 23, 26, 40 there were no changes in any of the growth factors examined in the present in the SDH and thalamus of diabetic monkeys. For example, BDNF plays a pivotal role in microglial activation and drives neuropathic pain in rodents. 58, 59 In contrast, TGFβ1, an anti-inflammatory growth factor, improves spinal sensitization in rodents. 60, 61 Moreover, cerebrospinal fluid levels of VEGF are correlated with pain in patients with failed back surgery syndrome. 62 Despite the abundance of these growth factors in the CNS, they were not significantly altered in diabetic monkeys. Conversely, accumulating evidence suggests that CB1 and CB2 receptors could be targets of anti-inflammatory therapeutics. 24, 25, 63 Activation of cannabinoid receptors also inhibits pain transmission in the SDH of rodents. 64 However, there was no change in CB1 and CB2 expression in the SDH of diabetic monkeys in the present study. Together, these findings indicate that growth factors and cannabinoid receptors may play a minimal role in modulating neuroinflammation in primates with T2DM.
It is worth noting that the upregulation of TNFα mRNA was correlated with an increase in TNFα protein levels in diabetic primates. This is in line with the results of a previous study that reported a similar correlation between changes in mRNA and protein levels. 13 Interestingly, the mRNA expression of proinflammatory mediators (i.e. IL-1β, TNFα, TLR1, and TLR2) in the SDH was positively correlated with plasma glucose levels in monkeys. It is important to point out that the SDH is more susceptible than the thalamus to changes due to a variety of neuroinflammatory modulators in diabetic monkeys. 13 Pharmacological treatments via the intrathecal route may be a viable therapeutic option because these proinflammatory mediators play a critical role in neuroinflammation. 26, 40, 56 The diabetic monkeys used in the present study had been diagnosed with T2DM for 3.1-6.8 years. Monkeys with a similar duration of T2DM showed impaired nerve conduction 29 and severe changes in epidermal innervation similar to patients with diabetic neuropathy, 30 suggesting that the diabetic monkeys used in the present study may have abnormal sensory processing. Future functional studies to determine whether diabetic monkeys exhibit mechanical hypersensitivity to noxious stimuli and to determine whether these behavioral responses could be altered by pharmacological interventions are warranted.
Collectively, the findings of the present study demonstrate the simultaneous upregulation of proinflammatory mediators (IL-1β, TNFα, TLR1, and TLR2) and downregulation of the anti-inflammatory mediator IL-10 in the SDH of diabetic monkeys. Unlike rodents, no changes were observed in TLR4, growth factor, and cannabinoid receptor mRNA expression in the SDH of diabetic monkeys. Together with recent findings, 13 the present study indicates that multiple ligands and receptors involved in neuroinflammation are simultaneously dysregulated (i.e. upregulation of proinflammatory cytokines, chemokines, and TLRs vs downregulation of opioid receptors and anti-inflammatory cytokines) in the spinal cord of diabetic monkeys. Drugs targeting several receptors instead of a single receptor may be more effective in managing neuroinflammatory symptoms in T2DM. Although it is challenging to recruit diabetic monkeys, this primate disease model not only helped demonstrate the pathological relevance of particular ligands and receptors involved in neuroinflammation, but may also facilitate the design of novel approaches for the treatment of neuroinflammation-driven adverse consequences in diabetic patients.
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